137 related articles for article (PubMed ID: 15370461)
1. Improved method for analysis of cysteinyldopa in human serum.
Arstrand K; Kullman A; Andersson R; Rasmuson T; Kågedal B
Scand J Clin Lab Invest; 2004; 64(6):559-64. PubMed ID: 15370461
[TBL] [Abstract][Full Text] [Related]
2. Development of a mass spectrometry method for the determination of a melanoma biomarker, 5-S-cysteinyldopa, in human plasma using solid phase extraction for sample clean-up.
Martin GB; Chiap P; Paquet P; Pierard G; de Tullio P; Martin Y; Rozet E; Hubert P; Crommen J; Fillet M
J Chromatogr A; 2007 Jul; 1156(1-2):141-8. PubMed ID: 17229429
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
[TBL] [Abstract][Full Text] [Related]
4. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
5. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
[TBL] [Abstract][Full Text] [Related]
6. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
7. High serum level of 5-S-cysteinyldopa in chronic renal failure does not always indicate melanoma progression.
Asada Y; Arakawa S; Fujiwara S; Sato F; Kaneda K
Br J Dermatol; 2004 Aug; 151(2):515-6. PubMed ID: 15327571
[No Abstract] [Full Text] [Related]
8. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
Hansson C; Rorsman H; Rosengren E; Tegner E
Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels.
Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T
Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166
[TBL] [Abstract][Full Text] [Related]
11. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
12. Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.
Omodaka T; Minagawa A; Uhara H; Wakamatsu K; Koizumi T; Yokokawa Y; Koga H; Okuyama R
J Dermatol; 2018 Nov; 45(11):1340-1344. PubMed ID: 30144152
[TBL] [Abstract][Full Text] [Related]
13. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
15. Identification of 5-S-cysteinyldopa by high performance liquid chromatography in biopsies from patients with dysplastic melanocytic nevi.
Halldin MM; Cook WS; Kawashima T; Crutcher WA; Fukuyama K
Cancer Res; 1987 Jan; 47(2):636-8. PubMed ID: 3098416
[TBL] [Abstract][Full Text] [Related]
16. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid.
Agrup G; Andersson T; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1975; 55(1):5-6. PubMed ID: 46673
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma.
Meyer T; Hauschild A; Kromminga A; Hartleb J; Arndt R; Christophers E; Stockfleth E
Melanoma Res; 2002 Oct; 12(5):471-7. PubMed ID: 12394189
[TBL] [Abstract][Full Text] [Related]
18. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel.
Kågedal B; Pettersson A
Clin Chem; 1983 Dec; 29(12):2031-4. PubMed ID: 6416708
[TBL] [Abstract][Full Text] [Related]
19. Increased serum levels of 5-S-cysteinyldopa and intercellular adhesion molecule-1 in a patient with a uterine amelanotic metastasis from a primary vaginal malignant melanoma.
Suenaga Y; Katabuchi H; Okamura H; Kageshita T; Ono T
Gynecol Oncol; 1999 Jan; 72(1):107-10. PubMed ID: 9889040
[TBL] [Abstract][Full Text] [Related]
20. A simple automated solid-phase extraction procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid chromatography-tandem mass spectrometry.
Knox S; Harris J; Calton L; Wallace AM
Ann Clin Biochem; 2009 May; 46(Pt 3):226-30. PubMed ID: 19389886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
